

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies

Adam S. Kittai,^{1*} Scott Best,¹ Bria Thurlow,¹ Vi Lam,¹ Taylor Hashiguchi,¹ Shaun Goodyear,¹ Daniel O. Persky,² Craig Okada,¹ Byung Park,¹ Stephen E. Spurgeon¹ and Alexey V. Danilov^{1,3}

¹Knight Cancer Institute, Oregon Health & Science University, Portland, OR; ²University of Arizona Cancer Center, Tucson, AZ and ³City of Hope Comprehensive Cancer Center, Duarte, CA, USA

^{*}Current address: Ohio State University, Columbus, OH, USA

Correspondence: ALEXEY V. DANILOV - adanilov@coh.org

doi:10.3324/haematol.2020.270298

SUPPLEMENTAL TABLE S1: PHASE 1 DOSING SCHEMA

| Dose Level (DL) | Entospletinib dose (starting on day -7 of run-in phase) | Obinutuzumab (Dosed cycles 1-6) |
|------------------------|--|---|
| -1 | 200 mg PO daily | C1D1: 100 mg IV C1 days 2, 8, 15: 1000 mg IV C2-C6: 1000 mg IV on day 1 |
| 1 | 200 mg PO twice daily | |
| 2 | 400 mg PO twice daily | |

SUPPLEMENTAL TABLE S2: CHARACTERISTICS OF PATIENTS ENROLLED ON STUDY

| Characteristics | All patients | |
|-------------------------------------|--------------|--------|
| | N = 23 | (%) |
| Age | | |
| < 65 years | 8 | (34.8) |
| ≥ 65 years | 15 | (65.2) |
| Sex | | |
| Male | 17 | (73.9) |
| Female | 6 | (26.1) |
| Race | | |
| White | 20 | (87.0) |
| Not Reported | 3 | (13.0) |
| ECOG performance status | | |
| 0 | 9 | (39.1) |
| 1 | 13 | (56.5) |
| 2 | 1 | (4.4) |
| Dose Level 1 | 6 | (26.1) |
| Dose Level 2 | 17 | (73.9) |
| Chronic lymphocytic leukemia | 21 | (91.3) |
| Follicular Lymphoma | 2 | (8.7) |

SUPPLEMENTAL TABLE S3. EFFICACY IN PATIENTS WITH CLL

| IWCLL Response after: | 3 Cycles | | 6 Cycles | | ≥9 Cycles | | Best Response | |
|-----------------------|----------|------|----------|------|-----------|------|---------------|------|
| | No. | % | No. | % | No. | % | No. | % |
| CR | 0 | 0 | 2 | 9.5 | 3 | 14.3 | 3 | 14.3 |
| PR | 11 | 52.4 | 11 | 52.4 | 11 | 52.4 | 11 | 52.4 |
| ORR | 11 | 52.4 | 13 | 52.4 | 14 | 66.7 | 14 | 66.7 |